Sun Pharmaceutical Industries has received a favorable legal ruling in the United States that clears a key hurdle in launching Leqselvi, its much-anticipated treatment for alopecia areata.
Cipla has received a reaffirmed ‘BUY’ rating from Prabhudas Lilladher following a pivotal regulatory development—the USFDA approval of its generic version of Abraxane (gAbraxane).
In a sharp divergence from its pandemic-era highs, Moderna Incorporated finds itself trading at a substantial discount, even as it sharpens focus on a curated pipeline of mRNA-based therapies.
Sun Pharmaceutical and Zydus Lifesciences shares could see pressure on Monday as both companies have issued limited recall for some pharmaceutical products in the US market.
KRChoksey Research has maintained its "BUY" recommendation for Aurobindo Pharma with a target price of Rs. 1,591, offering an upside potential of 33.5%.
